Find Pralatrexate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

3 RELATED EXCIPIENT COMPANIES

3EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 146464-95-1, Folotyn, 10-propargyl-10-deazaaminopterin, Hsdb 7786, Pdx, Pralatrexate(folotyn)
Molecular Formula
C23H23N7O5
Molecular Weight
477.5  g/mol
InChI Key
OGSBUKJUDHAQEA-WMCAAGNKSA-N
FDA UNII
A8Q8I19Q20

Pralatrexate
Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.
Pralatrexate is a Folate Analog Metabolic Inhibitor.
1 2D Structure

Pralatrexate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid
2.1.2 InChI
InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
2.1.3 InChI Key
OGSBUKJUDHAQEA-WMCAAGNKSA-N
2.1.4 Canonical SMILES
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
A8Q8I19Q20
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 10-propargyl-10-deazaaminopterin

2.3.2 Depositor-Supplied Synonyms

1. 146464-95-1

2. Folotyn

3. 10-propargyl-10-deazaaminopterin

4. Hsdb 7786

5. Pdx

6. Pralatrexate(folotyn)

7. Chebi:71223

8. N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-l-glutamic Acid

9. Nsc-754230

10. (2s)-2-((4-((1rs)-1-((2,4-diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic Acid

11. (2s)-2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioic Acid

12. A8q8i19q20

13. 146464-95-1 (racemic)

14. L-glutamic Acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-

15. Ncgc00242596-01

16. (2s)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic Acid

17. (2s)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic Acid

18. N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-l-glutamic Acid

19. L-glutamic Acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-

20. N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-l-glutamic Acid

21. Folotyn (tn)

22. Pralatrexate [usan]

23. Pralatrexate [usan:inn]

24. Pralatrexato

25. Pralatrexatum

26. Pralatrexat

27. Unii-a8q8i19q20

28. Pralatrexate [mi]

29. Pralatrexate [inn]

30. Pralatrexate [jan]

31. Pralatrexate [hsdb]

32. Dsstox_cid_28504

33. Dsstox_rid_82776

34. Pralatrexate [vandf]

35. Dsstox_gsid_48578

36. Schembl21633

37. Pralatrexate [mart.]

38. Pralatrexate [who-dd]

39. Gtpl6840

40. Pralatrexate (jan/usan/inn)

41. Chembl1201746

42. Dtxsid3048578

43. Schembl15075302

44. Bcpp000101

45. Pralatrexate [orange Book]

46. Ex-a2142

47. Tox21_112906

48. Bdbm50457437

49. Mfcd00920897

50. Nsc754230

51. S1497

52. Akos015966891

53. Am84423

54. Ccg-269517

55. Cs-0504

56. Db06813

57. Nsc 754230

58. S11194

59. 10-propargyl-10-deazaaminopterin, 95%

60. Ncgc00386226-01

61. Ac-28388

62. Bs-15438

63. Hy-10446

64. Cas-146464-95-1

65. P2645

66. Sw220187-1

67. D05589

68. Ab00443251-02

69. Ab00443251_04

70. 464p951

71. A884505

72. Q637059

73. Sr-01000941578

74. J-008227

75. Sr-01000941578-1

76. N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-l-glutamic Acid;pralatrexate

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 477.5 g/mol
Molecular Formula C23H23N7O5
XLogP3-0.9
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count11
Rotatable Bond Count10
Exact Mass477.17606686 g/mol
Monoisotopic Mass477.17606686 g/mol
Topological Polar Surface Area207 Ų
Heavy Atom Count35
Formal Charge0
Complexity809
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameFolotyn
PubMed HealthPralatrexate (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelFOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The structural for...
Active IngredientPralatrexate
Dosage FormSolution
RouteIntravenous
Strength40mg/2ml (20mg/ml); 20mg/ml (20mg/ml)
Market StatusPrescription
CompanyAllos

2 of 2  
Drug NameFolotyn
PubMed HealthPralatrexate (Injection)
Drug ClassesAntineoplastic Agent
Drug LabelFOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid. The structural for...
Active IngredientPralatrexate
Dosage FormSolution
RouteIntravenous
Strength40mg/2ml (20mg/ml); 20mg/ml (20mg/ml)
Market StatusPrescription
CompanyAllos

4.2 Therapeutic Uses

Aminopterin/ analogs & derivatives; Folic Acid Antagonists

National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)


Pralatrexate is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


T-cell lymphomas (TCL) are characterized by poor response to chemotherapy and generally poor outcome. While molecular profiling has identified distinct biological subsets and therapeutic targets in B-cell lymphomas, the molecular characterization of TCL has been slower. Surface markers expressed on malignant T-cells, such as CD2, CD3, CD4, CD25, and CD52 were the first TCL-specific therapeutic targets to be discovered. However, the presence of these receptors on normal T-cells means that monoclonal antibody (mAb)- or immunotoxin (IT)-based therapy in TCL inevitably results in variable degrees of immunosuppression. Thus, although some mAbs/IT have significant activity in selected subsets of TCL, more specific agents that target signaling pathways preferentially activated in malignant T-cells are needed. One such novel class of agents is represented by the histone deacetylase (HDAC) inhibitors. These molecules selectively induce apoptosis in a variety of transformed cells, including malignant T-cells, both in vitro and in vivo. Several HDAC inhibitors have been studied in TCL with promising results, and have recently been approved for clinical use. Immunomodulatory drugs, such as interferons and Toll Receptor (TLR) agonists have significant clinical activity in TCL, and are particularly important in the treatment of primary cutaneous subtypes (CTCL). Although most classical cytotoxic drugs have limited efficacy against TCL, agents that inhibit purine and pyrimidine metabolism, known as nucleoside analogues, and novel antifolate drugs, such as pralatrexate, are highly active in TCL. With improved molecular profiling of TCL novel pharmacological agents with activity in TCL are now being discovered at an increasingly rapid pace. Clinical trials are in progress and these agents are being integrated in combination therapies for TCL, both in the relapsed/refractory setting as well as front line.

PMID:20196721 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953129 Erter J et al; Curr Drug Targets (2009) (Epub ahead of print) .


4.3 Drug Warning

FOLOTYN can suppress bone marrow function, manifested by thrombocytopenia, neutropenia, and anemia. Dose modifications are based on ANC and platelet count prior to each dose.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


Treatment with FOLOTYN may cause mucositis. If /greater than or equal to/ Grade 2 mucositis is observed, dose should be modified.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


Patients should be instructed to take folic acid and receive vitamin B12 to potentially reduce treatment-related hematological toxicity and mucositis. ... Patients should take low-dose oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of FOLOTYN, and dosing should continue during the full course of therapy and for 30 days after the last dose of FOLOTYN. Patients should also receive a vitamin B12 intramuscular injection no more than 10 weeks prior to the first dose of FOLOTYN and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with FOLOTYN.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


Although FOLOTYN has not been formally tested in patients with renal impairment, caution is advised when administering FOLOTYN to patients with moderate to severe impairment. Monitor patients for renal function and systemic toxicity due to increased drug exposure.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


For more Drug Warnings (Complete) data for Pralatrexate (10 total), please visit the HSDB record page.


4.4 Drug Indication

Treatment of relapsed or refractory peripheral T-cell lymphoma.


FDA Label


treatment of peripheral T-cell lymphoma,


5 Pharmacology and Biochemistry
5.1 Pharmacology

Pralatrexate is a 10-deazaaminopterin analogue of methotrexate. Compared to methotrexate, pralatrexate binds to RTC-1 with 10-times the affinity and is a more potent substrate for FPGS. As a result, pralatrexate is better internalized and retained in cancer cells and is more cytotoxic. Km, pralatrexate = 0.3 mol/L; Km, methotrexate = 4.8 mol/L; Vmax/Km (rate of intracellular transport), pralatrexate = 12.6 Vmax/Km (rate of intracellular transport), methotrexate = 0.9


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
PRALATREXATE
5.2.2 FDA UNII
A8Q8I19Q20
5.2.3 Pharmacological Classes
Folate Analog Metabolic Inhibitor [EPC]
5.3 ATC Code

L01BA05


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01B - Antimetabolites

L01BA - Folic acid analogues

L01BA05 - Pralatrexate


5.4 Absorption, Distribution and Excretion

Absorption

Pralatrexate demonstrates linear pharmacokinetics with a multiphasic decline with both diasteromers over dose range of 30-325 mg/m^2. Bioavailability, nonformulated preparation = 13 - 20%


Route of Elimination

35% of drug is excreted unchanged in the urine (no difference between R- and S- pralatrexate). May be some net renal tubular excretion.


Volume of Distribution

Vss, R-pralatrexate = 37 L Vss, S-pralatrexate = 105 L


Clearance

R- pralatrexate = 191 mL/min S- pralatrexate = 417 mL/min Mean clearance of both enantiomers is 220 mL/min.


The pharmacokinetics of pralatrexate administered as a single agent at a dose of 30 mg/sq m administered as an intravenous push over 3-5 minutes once weekly for 6 weeks in 7-week cycles have been evaluated in 10 patients with PTCL. The total systemic clearance of pralatrexate diastereomers was 417 mL/min (S-diastereomer) and 191 mL/min (R-diastereomer).

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


Pralatrexate total systemic exposure (AUC) and maximum plasma concentration (Cmax) increased proportionally with dose (dose range 30-325 mg/sq m, including pharmacokinetics data from high dose solid tumor clinical studies). The pharmacokinetics of pralatrexate did not change significantly over multiple treatment cycles, and no accumulation of pralatrexate was observed.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


Pralatrexate diastereomers showed a steady-state volume of distribution of 105 L (S-diastereomer) and 37 L (R-diastereomer).

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


In vitro studies indicate that pralatrexate is approximately 67% bound to plasma proteins.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


For more Absorption, Distribution and Excretion (Complete) data for Pralatrexate (7 total), please visit the HSDB record page.


5.5 Metabolism/Metabolites

No involvement of CYP450 enzyme system or glucuronidases.


In vitro studies using human hepatocytes, liver microsomes and S9 fractions, and recombinant human CYP450 isozymes showed that pralatrexate is not significantly metabolized by the phase I hepatic CYP450 isozymes or phase II hepatic glucuronidases.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


5.6 Biological Half-Life

12-18 hours


The terminal elimination half-life of pralatrexate was 12-18 hours (coefficient of variance (CV) = 62-120%).

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


5.7 Mechanism of Action

The selectivity of pralatrexate for cancer cells is based upon the observation that cancer cells generally have an overexpression of reduced folate carrier protein-1 (RTC-1) compared to normal somatic cells. This carrier protein allows the entrance of pralatrexate into the cell. Upon entering the cell, folypolyglutamate synthase FPGS catalyzes the polyglutamination of pralatrexate so that it is retained inside the cell. Once inside, pralatrexate competitively inhibits dihydrofolate reductase (DHFR) and thymidylate synthase. Subsequent depletion of thymidine monophosphate (TMP) occurs so that the cancer cell is unable to synthesize DNA and RNA. As a result, the cancer cell cannot proliferate and is forced to undergo apoptosis. Pralatrexate is more effective against cells that are actively dividing.


Pralatrexate is a folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.

US Natl Inst Health; DailyMed. Current Medication Information for FOLOTYN (pralatrexate) injection (September 2009). Available from, as of March 17, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11995


This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methotrexate, and pemetrexed in NCI-H460 non-small cell lung cancer (NSCLC) cells. The tumor growth inhibition (TGI) was assessed using MV522 and NCI-H460 human NSCLC xenografts. Apparent K ( i ) values for DHFR inhibition were 45, 26, and >200 nM for pralatrexate, methotrexate, and pemetrexed, respectively. A significantly greater percentage of radiolabeled pralatrexate entered the cells and was polyglutamylatated relative to methotrexate or pemetrexed. In vivo, pralatrexate showed superior anti-tumor activity in both NSCLC models, with more effective dose-dependent TGI in the more rapidly growing NCI-H460 xenografts. Pralatrexate demonstrated a distinct mechanistic and anti-tumor activity profile relative to methotrexate and pemetrexed. Pralatrexate exhibited enhanced cellular uptake and increased polyglutamylation, which correlated with increased TGI in NSCLC xenograft models.

PMID:19221750 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728224 Izbicka E et al; Cancer Chemother Pharmacol 64 (5): 993-9 (2009).


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627669800,"product":"PRALATREXATE IH","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S.MCG PHARMA ILAC SAN.VE TIC.LTD.","customerCountry":"TURKEY","quantity":"0.02","actualQuantity":"15","unit":"GMS","unitRateFc":"3057.6","totalValueFC":"44340","currency":"USD","unitRateINR":220301.23333333334,"date":"31-Jul-2021","totalValueINR":"3304518.5","totalValueInUsd":"44340","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"3528361","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629657000,"product":"PRALATREXATE IH","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S.AROMA ILAC SAN. LTD.STI","customerCountry":"TURKEY","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"7650.9","totalValueFC":"14865","currency":"USD","unitRateINR":551250,"date":"23-Aug-2021","totalValueINR":"1102500","totalValueInUsd":"14865","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"4043702","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646850600,"product":"PRALATREXATE IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TOBIO NOVELFARMA","customerCountry":"TURKEY","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"4583.3","totalValueFC":"13146.2","currency":"USD","unitRateINR":334000,"date":"10-Mar-2022","totalValueINR":"1002000","totalValueInUsd":"13146.2","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"8827747","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722796200,"product":"PRALATREXATE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"POLIFARMA #LAC SAN.VE TIC.A.#","customerCountry":"TURKEY","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"4000","totalValueFC":"19666","currency":"USD","unitRateINR":329910.788,"date":"05-Aug-2024","totalValueINR":"1649553.94","totalValueInUsd":"19666","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"2977407","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""}]
31-Jul-2021
05-Aug-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Folotyn Manufacturers

A Folotyn manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Folotyn, including repackagers and relabelers. The FDA regulates Folotyn manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Folotyn API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Folotyn manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Folotyn Suppliers

A Folotyn supplier is an individual or a company that provides Folotyn active pharmaceutical ingredient (API) or Folotyn finished formulations upon request. The Folotyn suppliers may include Folotyn API manufacturers, exporters, distributors and traders.

click here to find a list of Folotyn suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Folotyn USDMF

A Folotyn DMF (Drug Master File) is a document detailing the whole manufacturing process of Folotyn active pharmaceutical ingredient (API) in detail. Different forms of Folotyn DMFs exist exist since differing nations have different regulations, such as Folotyn USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Folotyn DMF submitted to regulatory agencies in the US is known as a USDMF. Folotyn USDMF includes data on Folotyn's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Folotyn USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Folotyn suppliers with USDMF on PharmaCompass.

Folotyn WC

A Folotyn written confirmation (Folotyn WC) is an official document issued by a regulatory agency to a Folotyn manufacturer, verifying that the manufacturing facility of a Folotyn active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Folotyn APIs or Folotyn finished pharmaceutical products to another nation, regulatory agencies frequently require a Folotyn WC (written confirmation) as part of the regulatory process.

click here to find a list of Folotyn suppliers with Written Confirmation (WC) on PharmaCompass.

Folotyn NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Folotyn as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Folotyn API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Folotyn as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Folotyn and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Folotyn NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Folotyn suppliers with NDC on PharmaCompass.

Folotyn GMP

Folotyn Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Folotyn GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Folotyn GMP manufacturer or Folotyn GMP API supplier for your needs.

Folotyn CoA

A Folotyn CoA (Certificate of Analysis) is a formal document that attests to Folotyn's compliance with Folotyn specifications and serves as a tool for batch-level quality control.

Folotyn CoA mostly includes findings from lab analyses of a specific batch. For each Folotyn CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Folotyn may be tested according to a variety of international standards, such as European Pharmacopoeia (Folotyn EP), Folotyn JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Folotyn USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty